Loading patent…
AssigneeBecton, Dickinson and Company
InventorsRichard M. Ivey, Thomas M. Gentle JR., Richard L. Moore, Michael L. Towns, Nicholas Bachur JR., Robert W. Rosenstein, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice
Estimating the term…
The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.
A method of determining the status of sepsis in an individual, comprising:
A method of determining the status of sepsis in an individual, comprising:
A method of determining the status of sepsis in an individual, comprising:
A method of determining the status of sepsis in an individual, comprising:
A method of determining the status of sepsis in an individual, comprising:
A method of determining the status of sepsis in an individual, comprising:
A method of determining the status of sepsis in an individual, comprising determining changes in abundance of at least two host response nucleic acid biomarkers contained in a first biomarker profile obtained from a first biological sample from the individual compared to changes in abundance of said at least two host response nucleic acid biomarkers contained in biological samples from (i) a reference population that contracted sepsis and (ii) a reference population with SIRS, wherein the at least two host response nucleic acid biomarkers are selected from the group of host response nucleic acids set forth in any one of TABLES 2-10.
A method of determining the status of sepsis in an individual, comprising determining an abundance of at least two host response nucleic acid biomarkers contained in a first biomarker profile obtained from a first biological sample from the individual compared to an abundance of said at least two host response nucleic acid biomarkers contained in biological samples from (i) a reference population that contracted sepsis and (ii) a reference population with SIRS, wherein the at least two host response nucleic acid biomarkers are selected from the group of host response nucleic acids set forth in any one of TABLES 2-10.
A method of predicting the onset of sepsis in an individual, comprising:
A method of diagnosing SIRS in an individual, comprising:
A method of diagnosing SIRS in an individual, comprising:
A method of diagnosing SIRS in an individual, comprising comparing (i) a first biomarker profile generated from a biological sample taken from the individual at a single point in time with (ii) a reference biomarker profile generated from a reference population, wherein the individual's first biomarker profile and the reference biomarker profile comprise features that are measurable characteristics of a host response nucleic acid, and wherein the comparison comprises applying a decision rule that determines the status of SIRS in the individual.
A method of diagnosing SIRS in an individual, comprising:
A method of diagnosing SIRS in an individual, comprising comparing a measurable characteristic of at least one biomarker between (i) a first biomarker profile obtained from a first biological sample from the individual and (ii) a biomarker profile obtained from biological samples from a reference population, wherein the comparison classifies the individual as belonging to or not belonging to the reference population, wherein the individual's first biomarker profile and the reference biomarker profile comprise features that are measurable characteristics of a host response nucleic acid, and wherein the comparison diagnoses SIRS in the individual.
A method of diagnosing SIRS in an individual, comprising:
A method of diagnosing SIRS in an individual, comprising:
A method of diagnosing SIRS in an individual, comprising determining the abundance or a change in abundance of at least one biomarker obtained from a biological sample from the individual as compared to an abundance or change in an abundance of the at least one biomarker obtained from biological samples from a normal reference population, wherein the biomarkers are selected from the group consisting of the host response nucleic acids listed in any one of TABLES 2-10.
Dependencies are inferred from the claim text.